Untitled

Golse, Nicolas; Radenne, Sylvie; Rode, Agnès; Ducerf, C.; Mabrut, Jean‐Yves; Merle, Philippe

doi:10.6002/ect.2015.0299

Cited by 10 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety and feasibility of TKIs as NATs for HCC were then explored. [131][132][133][134][135][136][137] For patients with unresectable HCC, a subset analysis of a sorafenib study database showed a difference of approximately 10 months in the OS between patients who received and did not receive sorafenib before surgical resection. 136,138 No serious adverse effect of preoperative sorafenib administration was observed during and immediately after LR.…”

Section: Neoadjuvant Tki Strategymentioning

confidence: 99%

“…137 For patients with locally advanced HCC who were awaiting LT, the drop-out rate of patients receiving NAT was less than that of those treated with NAT for <6 months. 131,134 Downstaging from beyond the MC using neoadjuvant sorafenib therapy was correlated with better post-LT tumor event-free survival and longer OS. 139 However, compared with TACE alone, the combination of TACE and sorafenib before LT did not result in significant benefits.…”

Section: Neoadjuvant Tki Strategymentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant Therapy for Hepatocellular Carcinoma

Yin¹,

Chen²,

Liang³

et al. 2022

JHC

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is characterized by low resection and high postoperative recurrence rates, and conventional treatment strategies have failed to meet clinical needs. Neoadjuvant therapy (NAT) is widely employed in the routine management of several solid tumors because it increases resectability and reduces the rate of postoperative recurrence. However, a consensus has not been reached regarding the effects of NAT on HCC. As systemic therapy, particularly targeted therapy and immunotherapy, is given for HCC treatment, accumulating evidence shows that the “spring” of NAT for HCC is imminent. In the future, HCC researchers should focus on identifying biomarkers for treatment response, explore the mechanisms of resistance, and standardize the endpoints of NAT.

show abstract

Section: Neoadjuvant Tki Strategymentioning

confidence: 99%

Section: Neoadjuvant Tki Strategymentioning

confidence: 99%

Neoadjuvant Therapy for Hepatocellular Carcinoma

Yin¹,

Chen²,

Liang³

et al. 2022

JHC

View full text Add to dashboard Cite

show abstract

“…In recent years, molecular-targeted therapies have been used alone or in combination with locoregional therapies as pre-transplant treatments [ 120 , 121 ]. Sorafenib is an oral multi-kinase inhibitor that has been effective in prolonging time-to-progression in patients with advanced cancer in two large phase III trials [ 122 , 123 ].…”

Section: Variations Of Pre-transplant Locoregional Therapiesmentioning

confidence: 99%

“…Since sorafenib suppresses the growth of HCC by directly suppressing angiogenesis, it may be effective for bridging or downstaging when combined with TACE. However, at present, there are few reports that sorafenib was useful for bridging or downstaging before LT [ 121 ]. In addition to sorafenib, lenvatinib and regorafenib, which are also oral multi-kinase inhibitors, are used as therapeutic agents for advanced HCC.…”

Section: Variations Of Pre-transplant Locoregional Therapiesmentioning

confidence: 99%

Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation

Ogawa

Takada

2022

Cancers

View full text Add to dashboard Cite

Recently, there have been many reports of the usefulness of locoregional therapy such as transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma (HCC) as pretreatment before liver transplantation (LT). Locoregional therapy is performed with curative intent in Japan, where living donor LT constitutes the majority of LT due to the critical shortage of deceased donors. However, in Western countries, where deceased donor LT is the main procedure, LT is indicated for early-stage HCC regardless of liver functional reserve, and locoregional therapy is used for bridging until transplantation to prevent drop-outs from the waiting list or for downstaging to treat patients with advanced HCC who initially exceed the criteria for LT. There are many reports of the effect of bridging and downstaging locoregional therapy before LT, and its indications and efficacy are becoming clear. Responses to locoregional therapy, such as changes in tumor markers, the avidity of FDG-PET, etc., are considered useful for successful bridging and downstaging. In this review, the effects of bridging and downstaging locoregional therapy as a pretransplant treatment on the results of transplantation are clarified, focusing on recent reports.

show abstract

“…To date, there have been few reports of successful conversion after receiving sorafenib[ 142 - 144 ]. More evidence is required to support the role of sorafenib in neoadjuvant therapy because of the small sample size of clinical studies on sorafenib in neoadjuvant therapy[ 145 ]. Compared with other targeted drugs, lenvatinib leads to a higher response rate of approximately 40.6%[ 146 ].…”

Section: How To Implement Neoadjuvant Therapy In Hccmentioning

confidence: 99%

Neoadjuvant treatment strategies for hepatocellular carcinoma

Xu¹,

Lin²,

Zhang³

2021

WJGS

View full text Add to dashboard Cite

The incidence of hepatocellular carcinoma (HCC) remains high globally. Surgical treatment is the best treatment for improving the prognosis of patients with HCC. Neoadjuvant therapy plays a key role in preventing tumor progression and even downstaging HCC. The liver transplantation rate and resectability rate have increased for neoadjuvant therapy. Neoadjuvant therapy is effective in different stages of HCC. In this review, we summarized the definition, methods, effects, indications and contraindications of neoadjuvant therapy in HCC, which have significance for guiding treatment.

show abstract

Untitled

Abstract: These few case reports suggest the potential interest and feasibility of controlled studies to assess the efficacy and safety of sorafenib in neoadjuvant setting for hepatocellular carcinoma.

Cited by 10 publications

References 45 publications

Neoadjuvant Therapy for Hepatocellular Carcinoma

Neoadjuvant Therapy for Hepatocellular Carcinoma

Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation

Neoadjuvant treatment strategies for hepatocellular carcinoma

Contact Info

Product

Resources

About